Estimates Revisions Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Stocks
PLX
US74365A3095
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 732.50 ILa | -.--% |
|
+3.29% | +69.68% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- PLX Stock
- PLX Stock
- Consensus Protalix BioTherapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
